A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)

NCT01729754 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1090

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: Tildrakizumab 200 mg
DRUG: Tildrakizumab 100 mg
DRUG: Tildrakizumab Placebo
DRUG: Etanercept Placebo
DRUG: Etanercept 50 mg

Sponsor

Sun Pharmaceutical Industries Limited